|An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients|
B Györffy, A Lanczky, AC Eklund, C Denkert, J Budczies, Q Li, Z Szallasi
Breast cancer research and treatment 123 (3), 725-731, 2010
|Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes|
G Von Minckwitz, M Untch, JU Blohmer, SD Costa, H Eidtmann, ...
J Clin oncol 30 (15), 1796-1804, 2012
|The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014|
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ...
Annals of oncology 26 (2), 259-271, 2015
|Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer|
C Denkert, S Loibl, A Noske, M Roller, BM Muller, M Komor, J Budczies, ...
J Clin Oncol 28 (1), 105-113, 2010
|Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial|
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ...
Annals of oncology 25 (8), 1544-1550, 2014
|Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy|
C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ...
The lancet oncology 19 (1), 40-50, 2018
|Pembrolizumab for early triple-negative breast cancer|
P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ...
New England Journal of Medicine 382 (9), 810-821, 2020
|De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017|
G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
|Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization|
J Budczies, F Klauschen, BV Sinn, B Győrffy, WD Schmitt, ...
PloS one 7 (12), e51862, 2012
|Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial|
G Von Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai, ...
The lancet oncology 15 (7), 747-756, 2014
|Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative …|
C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ...
J Clin oncol 33 (9), 983-991, 2015
|Clinical relevance of host immunity in breast cancer: from TILs to the clinic|
P Savas, R Salgado, C Denkert, C Sotiriou, PK Darcy, MJ Smyth, S Loi
Nature reviews Clinical oncology 13 (4), 228-241, 2016
|Molecular alterations in triple-negative breast cancer—the road to new treatment strategies|
C Denkert, C Liedtke, A Tutt, G von Minckwitz
The Lancet 389 (10087), 2430-2442, 2017
|Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer|
G von Minckwitz, H Eidtmann, M Rezai, PA Fasching, H Tesch, ...
New England Journal of Medicine 366 (4), 299-309, 2012
|Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy|
W Weichert, A Röske, V Gekeler, T Beckers, C Stephan, K Jung, ...
British journal of cancer 98 (3), 604-610, 2008
|Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer|
M Kaufmann, G Von Minckwitz, EP Mamounas, D Cameron, LA Carey, ...
Annals of surgical oncology 19 (5), 1508-1516, 2012
|Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer ProgressionLipidomic Changes in Breast Cancer Progression|
M Hilvo, C Denkert, L Lehtinen, B Müller, S Brockmöller, ...
Cancer research 71 (9), 3236-3245, 2011
|Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib …|
R Salgado, C Denkert, C Campbell, P Savas, P Nuciforo, C Aura, ...
JAMA oncology 1 (4), 448-455, 2015
|Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …|
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (6), 311, 2017
|Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006|
M Kaufmann, G Von Minckwitz, HD Bear, A Buzdar, P McGale, H Bonnefoi, ...
Annals of Oncology 18 (12), 1927-1934, 2007